Lets actually take a closer look

Here is what I have taken from recent announcements

28th February 2017
Shareholder Webinar Presentation
What are you invested in?
- A is NOW a truly global Med Tech Company with a professional international corporate structure
- The business model/Company is de-risked and now starting to show reliable trends
- Professional management, enterprise specific systems and processes
- Globally qualified and industry specific BOD
- Senior Management (CFO, VP Tech Ops, etc.) internationally and sector experienced
- Organic sales moving towards profitability
- Multiple products to be launched
- M&A strategy being developed/non dilutive capital sources identified
- Blue sky opportunity with Immunotherapies (HSV and Oncology)
- Blue sky opportunity with TAVR

Backing up his words and to stand by his statements

15th March 2017
Admedus appoints Wayne Paterson as CEO
“When I took on the CEO role in an interim capacity, the Company was struggling but had
tremendous potential as a leader in regenerative medicine and med tech. Thanks to our
team’s efforts, we have quickly turned things around; by sharpening our focus and
streamlining operations, Admedus can now aggressively address our opportunities with
confidence. Accepting the Board’s request is in the best interests of the Company,
shareholders, and employees at this point in our company history. We have excellent
products to sell and a compelling story to tell. I am excited about the commercial
prospects of Admedus from ADAPT® and Infusion to TAVR and Immunotherapies.”

Loading up with some skin in the game

12th April 2017
Appendix 3B
-allotted 1,700,000 unlisted $0.34 options to employees
(If I had the opportunity I would allocate all possible options now before pending announcements
next week)

19th April 2017
Wayne preparing announcements for next week.